CI & Patent News 28/10/2010


Teva to Acquire Theramex, Merck KGaA’s European Based Women’s Health Business

Theramex is speciality pharmaceutical company focused on Women health and markets various products, like gynecology, osteoporosis, peri-menopause, menopause and contraceptives, in more than 50 countries. Theramex is developing new contraceptive combination of “nomegestrol acetate (2.5mg)/17beta-estradiol (1.5mg)”

(Yahoo Finance)

===========================================================

 

ACADIA and Biovail entered in collaboration agreement on Pimavanserin
Pimavanserin is selectively blocks serotonin 5-HT2A receptors in Phase III development for treating Parkinson’s disease psychosis

 

===========================================================

 

Pfizer faces italian antitrust probe over Xalatan patent (latanoprast)

 

===========================================================

 

Paragraph IV Litigations

Astellas sues Nycomed for Protopic ointment (Tacrolimus 0.1%) in USA
The patent infringement action was filed in the U.S. District Court for the District of New Jersey on October 27, 2010 requesting, among other things, an order that the date of approval of Nycomed’s ANDA not be earlier than the expiration of Astellas’ U.S. Patent Nos. 5,665,727 and 5,385,907 related to Protopic.

 

============================================================

 

Novartis sues Apotex for Rivastigmine (Complaint)
Astrazeneca sues watson for Rosuvastatin (Complaint)

 

============================================================

 

Advertisements

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s